Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma

Abstract

Peer reviewed

Mohammed M. Milhem, Hassane M. Zarour, Nashat Y. Gabrail, David J. Mauro, Norman M. Greenberg, William J. Slichenmyer and Arthur M. Krieg

Journal of clinical oncology, Vol.34(15_suppl), pp.TPS9593-TPS9593

05/20/2016

DOI: 10.1200/JCO.2016.34.15_suppl.TPS9593

View Online

Title: Subtitle: Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma
Creators: Mohammed M. Milhem - University of Iowa
Hassane M. Zarour - University of Pittsburgh
Nashat Y. Gabrail - Gabrail Cancer Center
David J. Mauro - Checkmate Pharmaceuticals, Cambridge, MA;
Norman M. Greenberg - Checkmate Pharmaceuticals, Cambridge, MA;
William J. Slichenmyer - Checkmate Pharmaceuticals, Cambridge, MA;
Arthur M. Krieg - Checkmate Pharmaceuticals, Cambridge, MA;
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.34(15_suppl), pp.TPS9593-TPS9593
DOI: 10.1200/JCO.2016.34.15_suppl.TPS9593
ISSN: 0732-183X
eISSN: 1527-7755
Language: English
Date published: 05/20/2016
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984363294402771

8 Record Views